Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CAMK2A | Q9UQM7 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835996 | 1.00 | EGFR (0.49) | EGFRALDH1A1LMNAGLACYP2C9 | |
| SCHEMBL30523650 | 0.84 | CAMK2A (0.51) | EGFRALDH1A1LMNAGLACYP2C9 | |
| SCHEMBL1142805 | 0.84 | CAMK2A (0.51) | EGFRALDH1A1LMNAGLACYP2C9 | |
| SCHEMBL29471363 | 0.82 | TSHR (0.53) | TSHRAKR1B1 | |
| SCHEMBL503667 | 0.82 | TSHR (0.53) | TSHRAKR1B1 | |
| SCHEMBL29419312 | 0.81 | TYR (0.60) | EGFRALDH1A1LMNAGLACYP2C9 | |
| SCHEMBL156238 | 0.81 | TYR (0.60) | EGFRALDH1A1LMNAGLACYP2C9 | |
| SCHEMBL868684 | 0.80 | KEAP1 (0.51) | LMNACYP2C9AKR1B1 | |
| SCHEMBL155333 | 0.79 | EGFR (0.70) | EGFRALDH1A1LMNAGLACYP2C9 | |
| SCHEMBL2535192 | 0.79 | EGFR (0.70) | EGFRALDH1A1LMNAGLACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235006-A1 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | Enterprise Therapeutics Limited (GB) | 2022-07-28 | — | — | US | disclosed |
| CN-114616226-A | Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders | TMEM16A有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021014166-A1 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | Enterprise Therapeutics Limited (GB) | 2021-01-28 | — | — | WO | disclosed |
| WO-2009097144-A1 | MOLECULAR PROBES FOR PET-IMAGING OF DOPAMINE NEUROTRANSMISSION AND NEUROENDOCRINE PROCESSES IN VIVO | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-06 | — | — | WO | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-0609244-B1 | METHOD OF PREPARING HALOGENATED HYDROXYPHENYLACETIC ACIDS | BASF AG (DE) | 1998-12-23 | — | — | EP | disclosed |
| EP-0609244-A1 | METHOD OF PREPARING HALOGENATED HYDROXYPHENYLACETIC ACIDS | BASF Aktiengesellschaft (DE) | 1994-08-10 | — | — | EP | disclosed |
| WO-1993008294-A1 | METHOD OF PREPARING HALOGENATED HYDROXYPHENYLACETIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | EGFR 3054/4885ALDH1A1 1096/4885LMNA 3800/4885 |
| US-20220235006-A1 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | TMEM109, TMEM70, TMEM120A | EGFR 1923/4885ALDH1A1 496/4885LMNA 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.